ABBVWatch

AbbVie Inc

$263.20

Community outlook

Bullish55%

Questions Discussion Earnings Data & analysis

Next report

Fri, 31 Jul 2026

in 2 daysbefore market open

EPS estimate

$3.67

Wall Street consensus

Revenue estimate

$17.1B

Wall Street consensus

Expected swing

±2.6%

±1σ by report day, from realized volatility

Also reporting that week:BA KO PYPL V ARM HOOD META MSFT

EPS outlook

Odds turned into a number: where the print lands if ABBV's usual surprise repeats — and what the crowd's beat odds imply on the same scale.

Street estimate

$•.••

the bar to clear

If history repeats

$•.••

•• of •• quarters beat

Crowd implies

—

needs more forecasts on the beat question

Typical range for the print: $•.•• – $•.••±1σ of past surprises
Beat odds implied by the record: ••%ceiling on •• quarters

A beat probability is a statement about where the print sits relative to the estimate. Scaled by how far recent quarters landed from the Street, it becomes a dollar figure. Not a forecast of the stock — companies fall on beats.

The crowd's read

Live odds from the community — tap through to make your own call.

Will AbbVie Inc beat Wall Street's EPS estimate at its next earnings report?

Beat the estimate? · 2 forecasting

67%

Forecast

Will AbbVie Inc close higher a week from now?

Nearest crowd call that settles after the report · 4 forecasting

53%

Forecast

The Street's stance

Analyst consensus — and whether it has been improving or souring into the print.

Buy

39 analysts · 31 buy · 8 hold · 0 sell

steady over the last 3 months

Estimate track record

Reported EPS against the Street's estimate, most recent first — the same feed our earnings questions settle on.

Beat rate

4 of 4

quarters beat the estimate

Avg surprise

+1.0%

vs EPS estimate

Quarter	Estimate	Actual	Surprise	Result
Mar 2026	$2.65	$2.65	+0.2%	BEAT
Dec 2025	$2.71	$2.71	+0.2%	BEAT
Sept 2025	$1.81

Fundamentals snapshot

Trailing-twelve-month figures for context around the print.

Market cap

$453.9B

EPS (TTM)

$2.05

P/E (TTM)

124.9

price ÷ trailing earnings

Revenue growth

+9.5%

TTM vs a year ago

Gross margin

72.0%

of revenue kept after costs

Net margin

5.8%

of revenue kept as profit

52-week range

$188 – $262

now $263.2

Beta

0.27

steadier than the market

Dividend yield

2.60%

Estimates and reported figures via Finnhub; crowd odds are AbbVie Inc forecasts on Probs. Information, not investment advice.